18780-69-3

Basic information

• Product Name: 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-phthalimido)butyl ester
• Synonyms: 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-phthalimido)butyl ester
• CAS NO: 18780-69-3
• Molecular Weight: 471.464
• Mol File: 18780-69-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-phthalimido)butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-phthalimido)butyl ester(18780-69-3)
• EPA Substance Registry System: 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-phthalimido)butyl ester(18780-69-3)

Safety Data

• Hazardous Substances Data: 18780-69-3(Hazardous Substances Data)

Upstream product

• 118-41-2 Eudesmic acid 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 
• 18780-67-1 4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoic acid 
• 18780-68-2 4-ethoxycarbonyloxy-3,5-dimethoxy-benzoyl chloride 
• 24697-75-4 4-ethoxycarbonyl-oxy-3,5-dimethoxy-benzoic acid (4-chloro)butyl ester 
• 1074-82-4 potassium phtalimide 

Relevant articles and documents

Leonurine hydrochloride-a new drug for the treatment of menopausal syndrome: Synthesis, estrogen-like effects and pharmacokinetics

This research aimed to investigate the estrogen-like effects of Leonurine hydrochloride (Leo). First, we developed a total synthesis of Leo from 3,4,5-trimethoxy-benzoic acid and the structure was confirmed through 1H NMR and mass spectrometry (MS). Then the estrogenic activity of Leo in vitro and in vivo was studied. The proliferation and proliferation inhibitory effects of Leo on MCF-7 cells and MDA-MB-231 cells indicate that Leo exerts estrogen-like effects through estrogen receptor α (ERα) and estrogen receptor β((ERβ) in vitro. Uterotrophic assay in juvenile mice showed that Leo has an estrogen-like effect in vivo, as it can promote the development of the uterus of juvenile mice, increase its uterine coefficient and the size of the uterine cavity, as well as the increased number of uterine glands and the thickened uterine wall. For further research, cyclophosphamide (CTX) was used to establish a mouse model of ovarian function decline. Through this model, we found that Leo can restore the estrous cycle of mice, increase the number of primordial and primary follicles in the ovaries of mice, and regulate the disordered hypothalamic-pituitary-ovarian (HPOA) axis of mice. Finally, the pharmacokinetics of Leo was studied and oral bioavailability of Leo was calculated to be 2.21%. Leo was synthesized and the estrogen-like effect in vitro and in vivo was confirmed as well as its pharmacokinetics.